1. Home
  2. VCEL vs ACGLO Comparison

VCEL vs ACGLO Comparison

Compare VCEL & ACGLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$39.36

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F

ACGLO

Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F

HOLD

Current Price

$20.56

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCEL
ACGLO
Founded
1989
N/A
Country
United States
Bermuda
Employees
N/A
5800
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
N/A
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
VCEL
ACGLO
Price
$39.36
$20.56
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$57.50
N/A
AVG Volume (30 Days)
575.4K
N/A
Earning Date
11-06-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
236.54
N/A
EPS
0.25
N/A
Revenue
$258,716,999.00
N/A
Revenue This Year
$17.86
N/A
Revenue Next Year
$18.55
N/A
P/E Ratio
$150.36
N/A
Revenue Growth
14.05
N/A
52 Week Low
$29.24
N/A
52 Week High
$63.00
N/A

Technical Indicators

Market Signals
Indicator
VCEL
ACGLO
Relative Strength Index (RSI) 59.96 46.65
Support Level $35.33 $20.10
Resistance Level $38.15 $20.73
Average True Range (ATR) 1.46 0.22
MACD 0.14 0.04
Stochastic Oscillator 98.17 69.17

Price Performance

Historical Comparison
VCEL
ACGLO

About VCEL Vericel Corporation

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

About ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F

Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.

Share on Social Networks: